For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corbus Pharmaceuticals Holdings (CRBP) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Corbus Pharmaceuticals Holdings is a member of the Medical sector. This group includes 833 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CRBP is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CRBP's full-year earnings has moved 7.43% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, CRBP has returned 14.73% so far this year. At the same time, Medical stocks have gained an average of 10.05%. As we can see, Corbus Pharmaceuticals Holdings is performing better than its sector in the calendar year.
Breaking things down more, CRBP is a member of the Medical - Drugs industry, which includes 175 individual companies and currently sits at #73 in the Zacks Industry Rank. On average, this group has gained an average of 19.22% so far this year, meaning that CRBP is slightly underperforming its industry in terms of year-to-date returns.
CRBP will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report
Original post
Zacks Investment Research